

## **Intellikine Announces Presentations at the AACR Annual Meeting**

LA JOLLA, CA – April 2, 2010 – Intellikine, Inc., a biopharmaceutical company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders, announced today that six presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.

### **Presentation details:**

Poster Title: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer

Presenter: Katti Jessen

Presentation Date/Time: Monday, April 19, 2010, 9:00 AM- 12:00 PM ET

Location: Exhibit Hall A-C, Poster Section 27

Abstract Number: 1668

Poster Title: INK128, an orally active TORC1/2 kinase inhibitor, shows broad antitumor activity and enhances efficacy of cytotoxic as well as targeted agents

Presenter: Linda Kessler

Presentation Date/Time: Tuesday, April 20, 2010, 2:00-5:00 PM ET

Location: Exhibit Hall A-C, Poster Section 24

Abstract Number: 4496

Poster Title: INK128, an orally active TORC1/2 kinase inhibitor demonstrates multi-pronged antitumor activity in preclinical models of renal cell carcinoma

Presenter: Shunyou Wang

Presentation Date/Time: Tuesday, April 20, 2010, 2:00-5:00 PM

Location: Exhibit Hall A-C, Poster Section 24

Abstract Number: 4488

Poster Title: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin

Presenter: David Fruman

Presentation Date/Time: Tuesday, April 19, 2010, 9:00 AM -12:00 PM ET

Location: Exhibit Hall A-C, Poster Section 32, Board Number: 16

Abstract Number: 1798

Poster Title: INK128, a novel TORC1/2 kinase inhibitor, demonstrates potent oral antitumor activity in a VEGF-reinforced murine model of breast cancer and enhances efficacy of bevacizumab

Presenter: Yesim Gökmen-Polar

Presentation Date/Time: Tuesday, April 20, 2010, 2:00-5:00 PM ET

Location: Exhibit Hall A-C, Poster Section 24

Abstract Number: 4490

Poster Title: The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies

Presenter: Simon Joel

Presentation Date/Time: Tuesday, April 20, 2010, 2:00-5:00 PM ET

Location: Exhibit Hall A-C, Poster Section 24

Abstract Number: 4489